Advances in the management of diabetic neuropathy

The authors review current advances in the therapy of diabetic neuropathy. The role of glycaemic control and management of cardiovascular risk factors in the prevention and treatment of neuropathic complications are discussed. As further options of pathogenetic ally oriented treatment, recent knowle...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Várkonyi Tamás
Körei Anna Erzsébet
Putz Zsuzsanna
Martos Tímea
Keresztes Katalin
Lengyel Csaba Attila
Nyiraty Szabolcs
Stirban Alin
Jermendy György
Kempler Péter
Dokumentumtípus: Cikk
Megjelent: 2017
Sorozat:MINERVA MEDICA 108 No. 5
doi:10.23736/S0026-4806.17.05257-0

mtmt:3230579
Online Access:http://publicatio.bibl.u-szeged.hu/16384
LEADER 02250nab a2200313 i 4500
001 publ16384
005 20201203144812.0
008 190805s2017 hu o 0|| zxx d
022 |a 0026-4806 
024 7 |a 10.23736/S0026-4806.17.05257-0  |2 doi 
024 7 |a 3230579  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a zxx 
100 1 |a Várkonyi Tamás 
245 1 0 |a Advances in the management of diabetic neuropathy  |h [elektronikus dokumentum] /  |c  Várkonyi Tamás 
260 |c 2017 
300 |a 419-437 
490 0 |a MINERVA MEDICA  |v 108 No. 5 
520 3 |a The authors review current advances in the therapy of diabetic neuropathy. The role of glycaemic control and management of cardiovascular risk factors in the prevention and treatment of neuropathic complications are discussed. As further options of pathogenetic ally oriented treatment, recent knowledge on benfotiamine and alpha-lipoic acid is comprehensively reviewed. Alpha-lipoic acid is a powerful antioxidant and clinical trials have proven its efficacy in ameliorating neuropathic signs and symptoms. Benfotiamine acts via the activation of transketolase and thereby inhibits alternative pathways triggered by uncontrolled glucose influx in the cells comprising polyol, hexosamine, protein-kinase-C pathways and formation of advanced glycation end products. Beyond additional forms of causal treatment, choices of symptomatic treatment will be summarized. The latter is mostly represented by the anticonvulsive agents pregabalin and gabapentin as well as duloxetine widely acknowledged as antidepressant. Finally, non-pharmacological therapeutic alternatives are summarized. The authors conclude that combination therapy should be more often suggested to our patients; especially the combination of pathogenetic and symptomatic agents. 
700 0 1 |a Körei Anna Erzsébet  |e aut 
700 0 1 |a Putz Zsuzsanna  |e aut 
700 0 1 |a Martos Tímea  |e aut 
700 0 1 |a Keresztes Katalin  |e aut 
700 0 1 |a Lengyel Csaba Attila  |e aut 
700 0 1 |a Nyiraty Szabolcs  |e aut 
700 0 1 |a Stirban Alin  |e aut 
700 0 1 |a Jermendy György  |e aut 
700 0 1 |a Kempler Péter  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/16384/1/MinervaMedicacikk2017.pdf  |z Dokumentum-elérés